published the results of a phase 3 clinical trial of tirzepatide, a dual GIP and GLP-1 receptor agonist, in patients with T2DM, showing significant results in glycemic control and weight loss (Rosenstock et al., 2021)
Not commonly used for general supplementation due to cost and invasiveness
A nasal spray is thus generally easier to administer than an intramuscular or subcutaneous injection
Protect Your Metabolism While Losing Weight When you go on a diet, you dont just lose fat you lose muscle too Losing muscle is a problem because muscle burns more calories than fat, and even burns calories when you are at rest. Harvard Health explains that muscle mass is one of the strongest determinants of basal metabolic rate (BMR), meaning the more muscle mass you have, the higher your BMR will generally be. Separately, Cleveland Clinic notes that cutting calories too drastically, especially protein, can lead the body to break down muscle for fuel, and it emphasizes that muscle mass plays an important role in keeping your metabolism powered up. John Peel explains it clearly in his GLP-1 support strength series: The goal is not just watching the scale move
GLP-1 Treatments, Semaglutide or Tirzepatide not only promotes weight loss but also decreases the likelihood of developing type 2 diabetes
has received honoraria for trial leadership from Amgen, Boehringer Ingelheim, Lilly USA, Metsera, NewAmsterdam, Novartis, Novo Nordisk and Pfizer, and honoraria for consultancy from Alveus, Amgen, Boehringer Ingelheim, F